CD8A and neoplasm: These results could be relevant for the treatment of patients with different types of solid cancer, since the expansion of suppressive KIR2DL2/S2+ CD8+ T cells in patients with HLA C1-ligands could be reversed with anti-KIR therapies, and conversely, expansion in vitro of KIR2DL1/S1+ CD8+ T cells favored by IL-12 could be assayed to determine its effectiveness as an anti-tumor cell therapy.